Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. (Nasdaq: NKTX) is a pioneering clinical-stage biotechnology company located in South San Francisco, California. Founded in 2015, Nkarta leverages proprietary natural killer (NK) cell expansion and engineering technologies to develop next-generation immunotherapies for the treatment of cancer and autoimmune diseases. The company’s mission is to harness the innate power of NK cells, which are the body's first line of defense, to create treatments that are more potent, better tolerated, and readily available to a broad patient population.
The core focus of Nkarta lies in its two lead candidates, NKX101 and NKX019. NKX101 is an off-the-shelf immunotherapy that targets NKG2D ligands on tumor cells, using engineered NK cells derived from healthy donors. This candidate shows promising results in treating acute myeloid leukemia (AML), with complete responses observed in high-risk patients. NKX019 targets CD19, a biomarker for B cell malignancies and autoimmune diseases such as lupus nephritis. This candidate has been designed to provide enhanced tumor cell targeting and greater persistence and activity.
Nkata's technological platform combines NK cell expansion and cryopreservation with advanced cell engineering techniques, including CRISPR-based genome engineering. This ensures a robust supply of NK cells and enables precise modification for enhanced therapeutic effectiveness. The company's cell therapies aim to be accessible for broad outpatient treatment, offering off-the-shelf solutions that minimize patient burden and reduce treatment delays.
Recent milestones include the clearance of an Investigational New Drug (IND) application by the U.S. FDA to evaluate NKX019 for lupus nephritis, expansion of their pipeline into autoimmune diseases, and strategic financial moves to extend their cash runway into 2026. Nkarta continues to provide updates on its clinical programs and looks forward to presenting additional data throughout 2024.
The company's financial backing comes from prominent investors such as SR One, NEA, and Novo Ventures, which underscores confidence in Nkarta's potential to revolutionize cell therapy. With a commitment to rigorous clinical development and strategic resource allocation, Nkarta is well-positioned to advance its innovative cell therapy candidates and deliver transformative treatments to patients in need.
Nkarta (NKTX) announced the opening of enrollment for Ntrust-2 and IND clearance for an investigator-sponsored trial (IST) evaluating NKX019, their allogeneic CD19-directed CAR NK-cell therapy. Ntrust-2 will evaluate the treatment across three parallel cohorts: systemic sclerosis, myositis, and ANCA-associated vasculitis. The IST will study NKX019 in myasthenia gravis patients.
The treatment protocol involves administering NKX019 on Days 0, 3, and 7 following lymphodepletion with cyclophosphamide. The therapy aims to provide a safe, accessible treatment option for autoimmune diseases through B-cell depletion, potentially enabling long-term remissions via immune system reset.
Patient dosing has begun in both Ntrust-1 and the IST for systemic lupus erythematosus, with preliminary data from Ntrust-1 and Ntrust-2 expected in 2025.
Nkarta (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer (NK) cell therapies, has announced its upcoming participation in the 7th Annual Evercore HealthCONx Conference. The company will participate in a fireside chat scheduled for December 4, 2024, at 2:10 p.m. ET.
The event will be accessible through a live webcast on Nkarta's website investor section, with a replay available for approximately 90 days following the presentation.
Nkarta (Nasdaq: NKTX), a company focused on engineered natural killer (NK) cell therapies, has announced its upcoming participation in the Stifel 2024 Healthcare Conference. The company will participate in a fireside chat scheduled for November 19, 2024, at 10:55 a.m. ET. The event will be webcast live on Nkarta's website investor section, with a replay available for approximately 90 days afterward.
Nkarta (NKTX) reported Q3 2024 financial results and corporate updates. The company has initiated patient dosing in both Ntrust-1 and investigator-sponsored trials of NKX019 for autoimmune diseases. Cash position stands at $405.3 million, expected to fund operations into late 2027. The company reported a net loss of $28.3 million ($0.39 per share) for Q3. Notably, Nkarta has decided to discontinue NKX019 development in lymphoma to focus on autoimmune diseases. Preliminary clinical data from Ntrust-1 and Ntrust-2 trials is planned for 2025.
Nkarta, a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced its participation in the upcoming H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 10, 2024, at 12:30 p.m. ET, featuring a fireside chat.
Investors and interested parties can access a live webcast of the event through the Investors section of Nkarta's website (www.nkartatx.com). For those unable to attend live, a replay of the webcast will be archived on the website for approximately 90 days. This conference participation provides an opportunity for Nkarta to showcase its progress and engage with the investment community.
Nkarta Inc. (NKTX) reported its Q2 2024 financial results and corporate highlights. Key points include:
1. Enrollment in Ntrust-2, a second clinical trial of NKX019 for autoimmune diseases (systemic sclerosis, myositis, vasculitis), expected to start by year-end 2024.
2. Preliminary clinical data from Ntrust-1 and Ntrust-2 trials planned for 2025.
3. Cash balance of $426.7 million as of June 30, 2024, expected to fund operations into late 2027.
4. Investigator-sponsored trial of NKX019 in systemic lupus erythematosus initiated at Columbia University.
5. Encouraging results from NKX019 retreatment in non-Hodgkin lymphoma patients.
6. Q2 2024 net loss of $25.0 million, or $0.34 per share.
7. R&D expenses were $23.1 million, and G&A expenses were $7.6 million for Q2 2024.
Nkarta Inc. (Nasdaq: NKTX) reported its Q2 2024 financial results and corporate highlights. Key points include:
1. Enrollment in Ntrust-2, a second clinical trial of NKX019 for autoimmune diseases, is expected to start by year-end 2024.
2. Preliminary clinical data from Ntrust-1 and Ntrust-2 trials planned for 2025.
3. Cash balance of $426.7 million as of June 30, 2024, expected to fund operations into late 2027.
4. Q2 2024 net loss of $25.0 million, or $0.34 per share.
5. R&D expenses were $23.1 million, while G&A expenses were $7.6 million for Q2 2024.
6. Nkarta presented follow-up data from its Phase 1 NKX019 trial in NHL, showing promising results in retreated patients.
7. Leadership updates include new President and Chief Medical Officer appointments.
Nkarta, Inc. (Nasdaq: NKTX) has announced the initiation of an investigator-sponsored trial (IST) of NKX019, their allogeneic, CD19-directed CAR NK-cell therapy, for patients with systemic lupus erythematosus (SLE). The trial, led by Dr. Anca D. Askanase at Columbia University Irving Medical Center, will enroll up to 6 SLE patients, regardless of renal involvement. This IST complements Nkarta's ongoing Phase 1 Ntrust-1 trial of NKX019 in lupus nephritis patients.
The single-center, open-label Phase 1 IST will evaluate safety, clinical outcomes, and include translational and biomarker studies. Patients will receive NKX019 on Days 0, 7, and 14 following lymphodepletion with cyclophosphamide. Nkarta believes NKX019's reduced-toxicity regimen could potentially benefit a broader patient population, including those with less advanced disease.
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, has announced significant leadership updates. Nadir Mahmood, Ph.D., has been appointed as President, sharing executive responsibilities with CEO Paul J. Hastings. Additionally, David R. Shook, M.D., has been promoted to Chief Medical Officer, Head of Research & Development.
These changes aim to accelerate the development and commercialization of NK cell therapies. Nkarta has recently initiated Ntrust-1, a clinical trial of NKX019 in lupus nephritis, and received FDA clearance for a second IND application for NKX019 in autoimmune diseases. The company expects to announce preliminary data from the Ntrust-1 and Ntrust-2 clinical trials in 2025.
Nkarta has initiated the Ntrust-1 clinical trial for NKX019 in lupus nephritis with the first patient now in screening.
The company has received FDA clearance for a second IND application for NKX019, enabling the launch of Ntrust-2 to treat systemic sclerosis, myositis, and vasculitis.
Both trials aim to assess the safety and efficacy of NKX019, an allogeneic CAR NK-cell therapy designed to target CD19-positive cells in B-cell mediated diseases.
Data from these trials are expected by 2025.
NKX019 leverages fludarabine-free lymphodepletion and offers on-demand dosing capabilities.
The Ntrust-1 trial involves administering NKX019 on Days 0, 7, and 14, while Ntrust-2 will adopt a different dosing schedule.
Each trial will initially enroll up to 12 patients.
FAQ
What is the current stock price of Nkarta (NKTX)?
What is the market cap of Nkarta (NKTX)?
What does Nkarta, Inc. specialize in?
Where is Nkarta, Inc. located?
What are Nkarta's lead therapy candidates?
How does Nkarta source its NK cells?
What are the recent achievements of Nkarta?
Who are some of Nkarta's investors?
How does Nkarta ensure its therapies are readily available?
What is the focus of Nkarta's NKX019 therapy?
What technological platforms does Nkarta use?
What future updates is Nkarta expected to provide?
